NASDAQ:INVA Innoviva (INVA) Stock Forecast, Price & News $13.23 +0.06 (+0.46%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$13.12▼$13.2950-Day Range$12.43▼$13.8952-Week Range$10.64▼$13.90Volume481,644 shsAverage Volume651,177 shsMarket Capitalization$861.27 millionP/E Ratio5.85Dividend YieldN/APrice Target$15.17 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Innoviva MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside14.8% Upside$15.17 Price TargetShort InterestBearish13.53% of Float Sold ShortDividend StrengthN/ASustainability-0.33Upright™ Environmental ScoreNews Sentiment1.02Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector760th out of 975 stocksPharmaceutical Preparations Industry358th out of 456 stocks 2.0 Analyst's Opinion Consensus RatingInnoviva has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.17, Innoviva has a forecasted upside of 14.8% from its current price of $13.21.Amount of Analyst CoverageInnoviva has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.53% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Innoviva has recently decreased by 0.11%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInnoviva has received a 60.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private equity funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for Innoviva is -0.33. Previous Next 3.9 News and Social Media Coverage News SentimentInnoviva has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Innoviva this week, compared to 1 article on an average week.Search Interest4 people have searched for INVA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows1 people have added Innoviva to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Innoviva is held by insiders.Percentage Held by Institutions99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 5.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 5.85, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 123.06.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Innoviva (NASDAQ:INVA) StockInnoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Read More INVA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVA Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comInnoviva (NASDAQ:INVA) Share Price Crosses Above 200 Day Moving Average of $12.51September 19, 2023 | finance.yahoo.comInnoviva to Participate in the Cantor Global Healthcare ConferenceSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 18, 2023 | finance.yahoo.comXACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in AdultsAugust 25, 2023 | finance.yahoo.comInnoviva Appoints Stephen Basso as Chief Financial OfficerAugust 3, 2023 | finance.yahoo.comInnoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressJuly 23, 2023 | fool.comInnoviva (NASDAQ: INVA)July 23, 2023 | finance.yahoo.comInvestors in Innoviva (NASDAQ:INVA) have unfortunately lost 11% over the last yearSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJuly 13, 2023 | benzinga.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsJuly 11, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage TherapeuticsJune 21, 2023 | seekingalpha.comInnoviva's Reward Isn't Worth The RiskJune 6, 2023 | finance.yahoo.comInnoviva to Participate in the Goldman Sachs Annual Global Healthcare ConferenceMay 23, 2023 | finance.yahoo.comInnoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous UseMay 12, 2023 | msn.comEF Hutton Reiterates Innoviva (INVA) Buy RecommendationMay 11, 2023 | finance.yahoo.comResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious DiseasesMay 11, 2023 | finance.yahoo.comIs There An Opportunity With Innoviva, Inc.'s (NASDAQ:INVA) 35% Undervaluation?May 9, 2023 | finance.yahoo.comInnoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressApril 28, 2023 | finance.yahoo.comInnoviva Announces Retirement of Board ChairmanApril 18, 2023 | msn.comInnoviva Rises on Advisory Committee Backing for Bacterial Pneumonia TherapyApril 18, 2023 | finance.yahoo.comFDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial InfectionsApril 17, 2023 | marketwatch.comInnoviva Shares Rise 7% After Pneumonia Drug's Approval by FDA CommitteeApril 17, 2023 | reuters.comUS FDA panel backs Innoviva's drug for multidrug-resistant bacterial infectionsApril 17, 2023 | marketwatch.comInnoviva Shares Halted as FDA Panel Reviews Sulbactam-Durlobactam >INVAApril 17, 2023 | finance.yahoo.comIs Innoviva (INVA) Stock Undervalued Right Now?April 17, 2023 | finance.yahoo.comSulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory CommitteeMarch 16, 2023 | seekingalpha.comStill Avoiding InnovivaSee More Headlines Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address INVA Company Calendar Last Earnings8/02/2023Today9/28/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees101Year Founded1996Price Target and Rating Average Stock Price Forecast$15.17 High Stock Price Forecast$22.50 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+14.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$2.26 Trailing P/E Ratio5.85 Forward P/E RatioN/A P/E GrowthN/ANet Income$213.92 million Net Margins80.35% Pretax Margin92.51% Return on Equity19.28% Return on Assets9.32% Debt Debt-to-Equity Ratio0.80 Current Ratio8.21 Quick Ratio7.02 Sales & Book Value Annual Sales$331.34 million Price / Sales2.60 Cash Flow$2.34 per share Price / Cash Flow5.66 Book Value$8.11 per share Price / Book1.63Miscellaneous Outstanding Shares65,100,000Free Float64,187,000Market Cap$860.62 million OptionableOptionable Beta0.53 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Pavel Raifeld C.F.A. (Age 39)Chief Exec. Officer Comp: $754.67kMs. Marianne Zhen CPA (Age 54)Chief Accounting Officer & Sec. Comp: $530.21kMr. Stephen Basso M.B.A.Chief Financial OfficerKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDMannKindNASDAQ:MNKDGeronNASDAQ:GERNOPKO HealthNASDAQ:OPKIntercept PharmaceuticalsNASDAQ:ICPTView All CompetitorsInsiders & InstitutionsAlberta Investment Management CorpSold 22,204 shares on 8/24/2023Ownership: 0.084%Virginia Retirement Systems ET ALBought 53,900 shares on 8/22/2023Ownership: 0.083%California State Teachers Retirement SystemSold 4,123 shares on 8/21/2023Ownership: 0.115%Teachers Retirement System of The State of KentuckyBought 1,101 shares on 8/21/2023Ownership: 0.033%Orion Portfolio Solutions LLCSold 2,373 shares on 8/17/2023Ownership: 0.164%View All Insider TransactionsView All Institutional Transactions INVA Stock - Frequently Asked Questions Should I buy or sell Innoviva stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares. View INVA analyst ratings or view top-rated stocks. What is Innoviva's stock price forecast for 2023? 3 analysts have issued 12 month price objectives for Innoviva's shares. Their INVA share price forecasts range from $10.00 to $22.50. On average, they expect the company's share price to reach $15.17 in the next year. This suggests a possible upside of 14.7% from the stock's current price. View analysts price targets for INVA or view top-rated stocks among Wall Street analysts. How have INVA shares performed in 2023? Innoviva's stock was trading at $13.25 at the beginning of 2023. Since then, INVA stock has decreased by 0.2% and is now trading at $13.22. View the best growth stocks for 2023 here. When is Innoviva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our INVA earnings forecast. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) issued its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported $0.08 earnings per share for the quarter. The biotechnology company earned $80.99 million during the quarter. Innoviva had a net margin of 80.35% and a trailing twelve-month return on equity of 19.28%. What ETFs hold Innoviva's stock? ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and iShares U.S. Pharmaceuticals ETF (IHE).Harbor Health Care ETF (MEDI). What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). What is Innoviva's stock symbol? Innoviva trades on the NASDAQ under the ticker symbol "INVA." Who are Innoviva's major shareholders? Innoviva's stock is owned by many different retail and institutional investors. Top institutional shareholders include Shaolin Capital Management LLC (0.00%), Dimensional Fund Advisors LP (5.99%), Renaissance Technologies LLC (5.52%), State Street Corp (3.66%), Geode Capital Management LLC (1.81%) and Pacer Advisors Inc. (1.35%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline. View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Innoviva's stock price today? One share of INVA stock can currently be purchased for approximately $13.22. How much money does Innoviva make? Innoviva (NASDAQ:INVA) has a market capitalization of $860.62 million and generates $331.34 million in revenue each year. The biotechnology company earns $213.92 million in net income (profit) each year or $2.26 on an earnings per share basis. How many employees does Innoviva have? The company employs 101 workers across the globe. How can I contact Innoviva? Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690. This page (NASDAQ:INVA) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.